Peptides for Energy and Fatigue: The Clinical Approach

Fatigue is one of the most common complaints in primary care, and it is one of the most easily misattributed. A patient who feels persistently tired reads about peptides for energy, sees marketing for NAD+ infusions, and wants to know whether one of these options will help. The answer is rarely a simple yes or no. It depends on what is actually causing the fatigue, what has been ruled out, and whether there is an appropriate clinical indication for prescribed therapy.

This article walks through how a licensed telehealth clinician approaches fatigue, what the foundational workup looks like, and where prescribed peptide or NAD+ protocols may fit when the broader picture supports it.

Why fatigue is harder than it looks

The word fatigue covers a wide range of experiences. Some patients describe physical exhaustion despite adequate sleep. Others describe cognitive fog and difficulty concentrating. Others describe a loss of motivation or pleasure that is closer to anhedonia than to fatigue in the strict sense. Each of these patterns has different likely causes and different appropriate interventions.

Furthermore, fatigue can be acute, subacute, or chronic. Acute fatigue lasting days is often related to acute illness, sleep deprivation, or specific stressors and tends to resolve on its own. Subacute fatigue lasting weeks may reflect ongoing process such as a viral illness recovery or a transient stressor. Chronic fatigue lasting months requires a structured workup because the differential is broad and some causes are serious.

A clinician evaluating a fatigue complaint does not assume any particular cause. The starting point is a structured history, a review of laboratory studies, and a focused examination of contributors that can be modified.

The foundational workup

For a patient presenting with fatigue, the typical initial workup includes a careful history and laboratory studies that screen for the most common medical causes.

Thyroid function should be evaluated. Hypothyroidism is a frequent cause of fatigue and is treatable. TSH is the standard screening test, with reflex to free T4 when indicated.

Complete blood count screens for anemia. Iron deficiency, B12 deficiency, and folate deficiency all cause fatigue and are correctable.

Comprehensive metabolic panel evaluates kidney function, liver function, electrolytes, and glucose. Diabetes and renal or hepatic dysfunction can present with fatigue.

Vitamin D level should be checked. Deficiency is common and often contributes to fatigue and low mood.

Iron studies, including ferritin, are useful even when the complete blood count is normal because low iron stores can cause fatigue before frank anemia develops. This is particularly relevant in menstruating individuals and athletes.

Sleep evaluation should be considered. Obstructive sleep apnea is common, often unrecognized, and presents with daytime fatigue. Patients with risk factors should be evaluated through home sleep testing or in-laboratory polysomnography.

Mental health screening should be part of the evaluation. Depression and anxiety frequently present with fatigue and are appropriately treated through evidence-based pathways.

Medication review is essential. Many medications cause fatigue, including some commonly prescribed ones. Identifying and addressing these contributors is often the most direct intervention.

Lifestyle factors deserve attention. Sleep duration and quality, alcohol use, caffeine timing, exercise, and nutritional intake all affect energy levels.

This workup catches a substantial percentage of fatigue cases. When something correctable is found, addressing it is the appropriate next step. When the workup is unrevealing, the clinician then considers other contributors, sometimes including hormonal patterns, recovery dynamics, or longevity-oriented protocols.

Where prescribed protocols may fit

For some patients, a comprehensive workup is unrevealing or only partially revealing, the foundational lifestyle factors are well managed, and the patient continues to experience reduced energy. In these cases, a clinician may consider whether a prescribed protocol is appropriate.

Several categories are sometimes discussed.

NAD+ protocols. NAD+ is a coenzyme central to cellular energy metabolism. It participates in oxidative phosphorylation, the process by which cells generate ATP from substrate. NAD+ levels decline with age. Prescribed NAD+ protocols, typically given parenterally, are used by some clinicians as part of longevity and performance plans. The rationale is supporting cellular energy capacity. Evidence varies, individual response varies, and the decision is patient-specific.

GHRH analog therapy. By supporting the natural growth hormone pulse, GHRH analogs may indirectly affect recovery, sleep architecture, and subjective energy in some patients. The evidence is mixed and the effects are gradual when they occur.

Other prescribed peptide protocols. Various peptides are used in specific clinical contexts under licensed care. Eligibility is patient-specific.

In all cases, the prescribed protocol enters the conversation only after the foundational work is complete. Skipping the workup and moving straight to a peptide protocol misses correctable contributors and substitutes a marketing-driven approach for a clinical one.

The NAD+ conversation

NAD+ deserves its own discussion because it has become one of the most marketed wellness interventions and is frequently misunderstood.

The biology is real. NAD+ is essential to mitochondrial function, sirtuin activity, DNA repair pathways, and cellular redox homeostasis. NAD+ levels do decline with age in many tissues. Restoring or supporting NAD+ status is a topic of active research.

The clinical translation is more nuanced. Several delivery routes exist:

Parenteral NAD+ administration, typically intravenous infusion or subcutaneous injection of NAD+ itself. This is given under prescribed protocols and aims to provide NAD+ directly.

Oral NAD+ precursors, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These are taken as supplements with the intention of raising endogenous NAD+ levels through precursor pathways. They are typically over-the-counter products, though some are available as prescribed compounded formulations.

Niacin and nicotinamide. The original NAD+ precursors. Inexpensive, well-studied, and used clinically for specific indications.

The evidence for clinical effects from each route is heterogeneous. Some studies support a benefit on specific outcomes, others do not, and the population-level data are still emerging. Individual response is highly variable.

A licensed clinician evaluating a patient interested in NAD+ does not promise a specific outcome. The clinician explains what is known and unknown, identifies whether the patient is an appropriate candidate, sets realistic expectations, and decides whether a protocol fits the broader plan.

What patients can realistically expect

A few honest framings are helpful.

Energy is multifactorial. Sleep, nutrition, training, stress, mood, and underlying medical conditions all contribute. A protocol that targets one piece of the puzzle cannot compensate for problems in other pieces.

Effects, when they occur, tend to develop over time. Patients sometimes describe a gradual sense of better recovery, less afternoon slump, or easier morning energy. They do not typically describe dramatic immediate changes.

Not every patient responds. Individual variability is substantial. Some patients describe meaningful subjective improvement, others notice little change, and others may experience side effects that limit utility.

The protocol is part of a plan, not a standalone solution. The clinician and patient revisit the plan periodically and adjust based on response.

Marketing claims should be discounted. The wellness industry has commercial incentives that do not always align with the evidence base. A clinician operates on the evidence and the individual clinical picture, not the marketing.

Who is not a candidate

Several factors caution against or contraindicate prescribed protocols in this category.

Patients with active malignancy or recent cancer history. Some hormone pathway interventions are avoided in this population. The clinician evaluates each case.

Patients with significant cardiac disease. Some intravenous protocols require caution, and the underlying disease should be optimally managed first.

Patients with substantial comorbidities for which the protocol is not appropriate.

Patients with untreated mental health conditions where the appropriate intervention is mental health treatment, not peptide therapy.

Patients seeking a quick fix for unevaluated fatigue. The right starting point is the workup, not the protocol.

A licensed clinician identifies these factors and makes appropriate decisions.

What "energy" actually means

It is worth pausing on what patients are asking for when they request something for "energy."

For some patients, the underlying experience is post-exertional fatigue. They feel fine at rest but exhaust easily and recover slowly. The clinical question is what is limiting recovery capacity.

For others, the experience is a baseline reduced energy state, where they feel tired throughout the day regardless of activity. This pattern often points toward sleep, mood, or hormonal factors.

For others, the issue is cognitive fatigue rather than physical fatigue. They can perform physical tasks but lose mental sharpness through the day. This pattern points toward sleep quality, hydration, blood glucose dynamics, and sometimes mental health factors.

For others, the issue is loss of motivation or anhedonia, which is a different experience than fatigue and points toward mental health evaluation.

A clinician unpacks what the patient actually means by "low energy" because the appropriate intervention varies by pattern.

Monitoring during therapy

When a prescribed protocol is initiated, monitoring is part of the standard of care.

Periodic clinical check-ins assess tolerance and any adverse effects.

Laboratory monitoring as appropriate to the specific protocol.

Subjective assessment of energy, often supported by simple self-report tools or wearables.

Reassessment of the protocol if expected effects are not occurring or if side effects are limiting.

The patient is engaged in an ongoing clinical relationship, not a transactional purchase.

A note on intravenous "energy" services

The wellness industry includes a range of intravenous infusion services marketed for energy, recovery, and various wellness claims. Some of these services operate within licensed clinical models with physician oversight, sterile preparation, and appropriate patient evaluation. Others operate outside that framework.

Patients considering any intravenous service should verify:

The clinician overseeing the service is appropriately licensed.

The medications used are prepared in a licensed pharmacy under appropriate sterile conditions.

A patient evaluation occurs before the infusion, not just a checklist signature.

The setting has appropriate equipment for managing potential adverse events.

The same evaluation framework applies whether the protocol is given by infusion, injection, or any other route.

How TelePeptide Health approaches this

Within the TelePeptide Health model, fatigue is evaluated as a clinical complaint that warrants a structured workup before any prescribed protocol is considered. A licensed clinician reviews history, labs, and contributors that may be modifiable. Sleep disorders, thyroid function, anemia, vitamin status, mental health, and lifestyle factors are addressed before peptide therapy enters the conversation.

When prescribed protocols are appropriate, they are filled at a 503A compounding pharmacy with documented quality systems, and the patient is followed with periodic check-ins. The clinical picture, not marketing claims, drives the decision.

The takeaway

Fatigue is common, multifactorial, and often correctable through evaluation and targeted intervention. The wellness market promises faster, more direct paths through peptide products and infusion services, but those promises do not consistently match the underlying biology or the individual clinical picture.

A licensed clinician evaluating a patient with fatigue starts with the foundational workup. When something correctable is found, the appropriate intervention is addressing it. When the workup is unrevealing and the foundation is in place, prescribed peptide or NAD+ protocols may be considered as part of a broader plan in selected cases.

The right way to find out whether one of these protocols is appropriate for a particular patient is the same as the right way to address any health complaint: a thorough evaluation by a licensed clinician, honest discussion of what is known and unknown, and an ongoing relationship that supports safe, individualized care.

Skipping the workup and ordering a marketed product online may feel faster, but it usually delays actually addressing the cause of the fatigue and operates outside the legal framework for prescribed therapy. A telehealth visit with a licensed clinician is the more direct path to an honest answer.